Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Unlucky? Lilly Leads Big Pharma In US FDA Complete Response Letters

May 26 2023

• By Bridget Silverman

review - gum on shoe — • Source: Shutterstock

Related Content

Keeping Track: US FDA Approves Novartis’ Scemblix; Lilly Submits Tirzepatide, Withdraws Tanezumab

Oct 30 2021

US FDA Rejects Lilly’s Bid For Donanemab Accelerated Approval In Early Alzheimer’s

Jan 20 2023

TikTok Moment For BeiGene, Junshi As FDA Looks At China PD-1s

Apr 12 2023

Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic

Sep 22 2022

Takeda Raises Full-Year Outlook On Strong Mainstays

Feb 04 2022

Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval

Feb 02 2023

FibroGen’s Roxadustat On The Rocks After Phase III Myelodysplastic Syndrome Failure

May 05 2023

Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL

Apr 14 2023

Related Companies

Eli Lilly and Company

Gilead Sciences, Inc.

GSK plc

Spero Therapeutics, Inc.

Takeda Pharmaceutical Co. Ltd.

Merck & Co., Inc.

Novo Nordisk A/S

Pfizer Inc.

AstraZeneca PLC

Meiji Seika Pharma Co., Ltd

Hanmi Pharmaceutical Co., Ltd.

Spectrum Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc.

Athenex, Inc.

Azurity Pharmaceuticals, Inc.

FibroGen, Inc.

Akebia Therapeutics, Inc.

Innovent Biologics, Inc.

Incyte Corporation

Loxo Oncology at Lilly

Dermira Inc.

Regeneron Pharmaceuticals, Inc.

Additional Topics

United States Complete Response Letters Drug Approval Standards Drug Review Regulation US FDA Performance Tracker BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window